-
Bayer Secures Multiple Procurement Deals at the 6th CIIE
•
At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced a series of procurement agreements with several Class 3A hospitals in China. Among these institutions is the prestigious Fourth Affiliated Hospital of China Medical University. Bayer’s Commitment to Healthcare Partnerships in ChinaThe agreements signed during…
-
ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions
•
Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550), focusing on the digestive enzyme field. The collaboration aims to explore and promote product development in the digestive tract health sector, with no financial details disclosed. Focus on Digestive Tract Health and…
-
Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia
•
Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in Australia to conduct a first-in-human clinical trial for its pipeline candidate, SRSD107. This next-generation small interfering RNA (siRNA) therapeutic is under development for the treatment of thromboembolic disorders and targets coagulation factor XI (FXI). Notably,…
-
ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study
•
Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in the United States for its intravenous oncolytic virus product, MVR-T3011 IV. The trial, which focuses on late stage patients with various tumor types, yielded “exceptional” safety results and demonstrated initial efficacy for certain indicationsThe study…
-
Establishment Labs Receives NMPA Approval for Motiva Silicone Gel-Filled Breast Implants
•
US-based medical technology company Establishment Labs Holdings Inc., (NASDAQ: ESTA) has announced that it has received product approval from China’s National Medical Products Administration (NMPA) for its Motiva silicone gel-filled breast implants. This marks the company’s first approval in China, the world’s second-largest market for breast implants. Originally approved in…
-
AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines,…
-
Novartis’ Remibrutinib Meets Milestones in Late-Stage Chronic Spontaneous Urticaria Studies
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that two late-stage studies for its Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, used in the treatment of chronic spontaneous urticaria (CSU), have successfully met all primary and secondary endpoints at the 12-week mark of a 52-week trial. After three months of treatment…
-
CStone Pharmaceuticals Enters Licensing Agreement with Allist Pharmaceuticals for Gavreto in China
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced a licensing agreement with Allist Pharmaceuticals Co., Ltd, granting the Shanghai-based biotech exclusive commercial promotion rights to Gavreto (pralsetinib) in mainland China. CStone retains development, regulatory filing, and other rights excluding promotion in mainland China. Under the agreement, CStone will receive an undisclosed…
